These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 38143353)

  • 21. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.
    Janelidze S; Pannee J; Mikulskis A; Chiao P; Zetterberg H; Blennow K; Hansson O
    JAMA Neurol; 2017 Dec; 74(12):1492-1501. PubMed ID: 29114726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum.
    Lee J; Jang H; Kang SH; Kim J; Kim JS; Kim JP; Kim HJ; Seo SW; Na DL
    J Korean Med Sci; 2020 Nov; 35(44):e361. PubMed ID: 33200589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amyloid PETs are commonly negative in suspected Alzheimer's disease with an increase in CSF phosphorylated-tau protein concentration but an Aβ42 concentration in the very high range: a prospective study.
    Manca C; Rivasseau Jonveaux T; Roch V; Marie PY; Karcher G; Lamiral Z; Malaplate C; Verger A
    J Neurol; 2019 Jul; 266(7):1685-1692. PubMed ID: 30963253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.
    Álvarez I; Aguilar M; González JM; Ysamat M; Lorenzo-Bosquet C; Alonso A; Tartari JP; Romero S; Diez-Fairen M; Carcel M; Pujalte F; Pastor P
    J Alzheimers Dis; 2018; 61(1):135-143. PubMed ID: 29154286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort.
    Zwan M; van Harten A; Ossenkoppele R; Bouwman F; Teunissen C; Adriaanse S; Lammertsma A; Scheltens P; van Berckel B; van der Flier W
    J Alzheimers Dis; 2014; 41(3):801-7. PubMed ID: 24705549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of tau deposition using
    Bullich S; Mueller A; De Santi S; Koglin N; Krause S; Kaplow J; Kanekiyo M; Roé-Vellvé N; Perrotin A; Jovalekic A; Scott D; Gee M; Stephens A; Irizarry M
    Alzheimers Res Ther; 2022 Jul; 14(1):105. PubMed ID: 35897078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.
    Molinuevo JL; Blennow K; Dubois B; Engelborghs S; Lewczuk P; Perret-Liaudet A; Teunissen CE; Parnetti L
    Alzheimers Dement; 2014 Nov; 10(6):808-17. PubMed ID: 25150736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
    J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
    Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP
    Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concordance between brain
    Rubí S; Noguera A; Tarongí S; Oporto M; García A; Vico H; Espino A; Picado MJ; Mas A; Peña C; Amer G
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(1):3-8. PubMed ID: 28645685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
    Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
    J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Two Analytical Platforms in Cerebrospinal Fluid Biomarkers for the Classification of Alzheimer's Disease Spectrum with Amyloid PET Imaging.
    Lim HJ; Park JE; Kim BC; Choi SM; Song MK; Cho SH; Seo HJ; Kim J; Song HC; Choi KY; Lee JJ; Kim HW; Ha JM; Song WK; Park SG; Lee JS; Lee KH
    J Alzheimers Dis; 2020; 75(3):949-958. PubMed ID: 32390627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
    Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
    Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium.
    Somers C; Struyfs H; Goossens J; Niemantsverdriet E; Luyckx J; De Roeck N; De Roeck E; De Vil B; Cras P; Martin JJ; De Deyn PP; Bjerke M; Engelborghs S
    J Alzheimers Dis; 2016 Aug; 54(1):383-95. PubMed ID: 27567807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse.
    Alcolea D; Pegueroles J; Muñoz L; Camacho V; López-Mora D; Fernández-León A; Le Bastard N; Huyck E; Nadal A; Olmedo V; Sampedro F; Montal V; Vilaplana E; Clarimón J; Blesa R; Fortea J; Lleó A
    Ann Clin Transl Neurol; 2019 Sep; 6(9):1815-1824. PubMed ID: 31464088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between CSF biomarkers of Alzheimer's disease and global cognition in a psychogeriatric clinic cohort.
    Radanovic M; Oshiro CA; Freitas TQ; Talib LL; Forlenza OV
    Braz J Psychiatry; 2019; 41(6):479-484. PubMed ID: 31166546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
    Parnetti L; Chiasserini D; Eusebi P; Giannandrea D; Bellomo G; De Carlo C; Padiglioni C; Mastrocola S; Lisetti V; Calabresi P
    J Alzheimers Dis; 2012; 29(1):229-38. PubMed ID: 22232006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.
    Fagan AM; Shaw LM; Xiong C; Vanderstichele H; Mintun MA; Trojanowski JQ; Coart E; Morris JC; Holtzman DM
    Arch Neurol; 2011 Sep; 68(9):1137-44. PubMed ID: 21555603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.